Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ropanicant - Suven Life Sciences

Drug Profile

Ropanicant - Suven Life Sciences

Alternative Names: SUVN-911

Latest Information Update: 29 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suven Life Sciences
  • Class Antidepressants; Aza compounds; Cyclohexanes; Cyclopropanes; Heterocyclic bicyclo compounds; Pyridines; Small molecules
  • Mechanism of Action Alpha4beta2 nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Major depressive disorder

Most Recent Events

  • 28 Jun 2020 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in USA (PO, Tablet)
  • 16 Jul 2018 Suven Life Sciences Limited completes a phase I trial in Major depressive disorder (In volunteers) in USA (PO) (NCT03551288)
  • 22 May 2018 Phase-I clinical trials in Major depressive disorder (In volunteers) in USA (PO) (NCT03551288)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top